EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Apelin Is a Prototype of Novel Drugs for the Treatment of Acute Myocardial Infarction and Adverse Myocardial Remodeling

Sergey V Popov, Leonid N Maslov iD, Alexandr V Mukhomedzyanov iD, Boris K Kurbatov iD, Alexandr S Gorbunov, Michail Kilin, Viacheslav N Azev iD, Maria S Khlestkina, Galina Z Sufianova

Pharmaceutics · 22.03.2023 · 15 (3) · 1029

DOI: 10.3390/pharmaceutics15031029 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 22.03.2023. Verfasst von Sergey V Popov und 8 weiteren Autor:innen. Beteiligte Einrichtung: Tomsk National Research Medical Center, Cardiology Research Institute, The Russian Academy of Sciences, Kyevskaya 111A, Tomsk 634012, Russia. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: State assignment.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In-hospital mortality in patients with ST-segment elevation myocardial infarction (STEMI) is 5–6%. Consequently, it is necessary to develop fundamentally novel drugs capable of reducing mortality in patients with acute myocardial infarction. Apelins could be the prototype for such drugs. Chronic administration of apelins mitigates adverse myocardial remodeling in animals with myocardial infarction or pressure overload. The cardioprotective effect of apelins is accompanied by blockage of the MPT pore, GSK-3β, and the activation of PI3-kinase, Akt, ERK1/2, NO-synthase, superoxide dismutase, glutathione peroxidase, matrix metalloproteinase, the epidermal growth factor receptor, Src kinase, the mitoKATP channel, guanylyl cyclase, phospholipase C, protein kinase C, the Na+/H+ exchanger, and the Na+/Ca2+ exchanger. The cardioprotective effect of apelins is associated with the inhibition of apoptosis and ferroptosis. Apelins stimulate the autophagy of cardiomyocytes. Synthetic apelin analogues are prospective compounds for the development of novel cardioprotective drugs.

Schlagwörter

Stichwörter der Autor:innen

adverse remodelingapelinheartischemia/reperfusion

Autor:innen und Institutionen

  • Tomsk National Research Medical Center, Cardiology Research Institute, The Russian Academy of Sciences, Kyevskaya 111A, Tomsk 634012, Russia.
  • Branch of Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, The Russian Academy of Sciences, Pushchino 142290, Russia.
  • Department of Pharmacology, Tyumen State Medical University, Tyumen 625023, Russia.

ORCID-Profile: Leonid N Maslov, Alexandr V Mukhomedzyanov, Boris K Kurbatov, Viacheslav N Azev

Förderung

  • State assignment

Zitieren

APA

Popov, S. V., Maslov, L. N., Mukhomedzyanov, A. V., Kurbatov, B. K., Gorbunov, A. S., Kilin, M., Azev, V. N., Khlestkina, M. S., & Sufianova, G. Z. (2023). Apelin Is a Prototype of Novel Drugs for the Treatment of Acute Myocardial Infarction and Adverse Myocardial Remodeling. Pharmaceutics, 15(3), 1029. https://doi.org/10.3390/pharmaceutics15031029

Vancouver

Popov SV, Maslov LN, Mukhomedzyanov AV, Kurbatov BK, Gorbunov AS, Kilin M, et al. Apelin Is a Prototype of Novel Drugs for the Treatment of Acute Myocardial Infarction and Adverse Myocardial Remodeling. Pharmaceutics. 2023;15(3):1029. doi:10.3390/pharmaceutics15031029

BibTeX
@article{Popov2023,
  author = {Popov, Sergey V and Maslov, Leonid N and Mukhomedzyanov, Alexandr V and Kurbatov, Boris K and Gorbunov, Alexandr S and Kilin, Michail and Azev, Viacheslav N and Khlestkina, Maria S and Sufianova, Galina Z},
  title = {Apelin Is a Prototype of Novel Drugs for the Treatment of Acute Myocardial Infarction and Adverse Myocardial Remodeling},
  journal = {Pharmaceutics},
  year = {2023},
  volume = {15},
  number = {3},
  pages = {1029},
  doi = {10.3390/pharmaceutics15031029}
}
Kostenlos starten →